TRANSCEND — Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma (TRANSCEND NHL 001)

Phase 1 · 2020 · Diffuse Large B-Cell Lymphoma

Design

Single-arm, seamless-design study of the CD19-directed CAR T-cell product lisocabtagene maraleucel at escalating dose levels.

Population

Relapsed or refractory large B-cell lymphoma after at least two prior therapies.

Primary Endpoint

objective response rate (ORR)

Key Result

ORR 73% with 53% complete responses and comparatively low rates of grade ≥3 cytokine release syndrome (2%) and neurotoxicity (10%).

Guideline Impact

NCCN-listed lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma